Terms: = Cervical cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB
567 results:
1. Integrated In-Silico and In Vitro analysis to Decipher the contribution of bisphenol-A in cervical cancer.
Khan NG; Adiga D; Rai PS; Kabekkodu SP
Toxicology; 2024 May; 504():153791. PubMed ID: 38555994
[TBL] [Abstract] [Full Text] [Related]
2. Plumbagin as a preferential lead molecule to combat egfr-driven matrix abundance and migration of cervical carcinoma cells.
Krishnamoorthy S; Sabanayagam R; Periyasamy L; Muruganantham B; Muthusami S
Med Oncol; 2024 Mar; 41(4):89. PubMed ID: 38520625
[TBL] [Abstract] [Full Text] [Related]
3. Thermo-sensitive PLGA-PEG-PLGA hydrogel for sustained release of EGF to inhibit cervical cancer recurrence.
Piao L; Xiang P; Zhou Y; Zhao W; Yang T; Xia S; Gao G; Chen K; Li D
Colloids Surf B Biointerfaces; 2024 Apr; 236():113795. PubMed ID: 38428207
[TBL] [Abstract] [Full Text] [Related]
4. The m6A methyltransferase RBM15 affects tumor cell stemness and progression of cervical cancer by regulating the stability of lncRNA HEIH.
Quan Y; Zhou M; Li J; Yang Y; Guo J; Tang T; Liu P
Exp Cell Res; 2024 Mar; 436(2):113924. PubMed ID: 38280435
[TBL] [Abstract] [Full Text] [Related]
5. Cyclic increase in the ADAMTS1-L1CAM-egfr axis promotes the EMT and cervical lymph node metastasis of oral squamous cell carcinoma.
Chien MH; Yang YC; Ho KH; Ding YF; Chen LH; Chiu WK; Chen JQ; Tung MC; Hsiao M; Lee WJ
Cell Death Dis; 2024 Jan; 15(1):82. PubMed ID: 38263290
[TBL] [Abstract] [Full Text] [Related]
6. Network pharmacology combined with experimental verification to explore the potential mechanism of naringenin in the treatment of cervical cancer.
Zhou J; Li H; Wu B; Zhu L; Huang Q; Guo Z; He Q; Wang L; Peng X; Guo T
Sci Rep; 2024 Jan; 14(1):1860. PubMed ID: 38253629
[TBL] [Abstract] [Full Text] [Related]
7. Whether specific genetic feature predicted immunotherapy efficacy: A case report.
Chen J; Pang L; He L; Li T; Cheng X
Medicine (Baltimore); 2024 Jan; 103(2):e36922. PubMed ID: 38215117
[TBL] [Abstract] [Full Text] [Related]
8. LncRNA ABHD11-AS1 activates egfr signaling to promote cervical cancer progression by preventing FUS-mediated degradation of ABHD11 mRNA.
Yang T; Tian S; Zhao J; Pei M; Zhao M; Yang X
Cell Cycle; 2023; 22(23-24):2538-2551. PubMed ID: 38146687
[TBL] [Abstract] [Full Text] [Related]
9. Survival rate of cervical cancer in Asian countries: a systematic review and meta-analysis.
Vali M; Maleki Z; Nikbakht HA; Hassanipour S; Kouhi A; Nazemi S; Hajizade-Valokolaee M; Nayeb M; Ghaem H
BMC Womens Health; 2023 Dec; 23(1):671. PubMed ID: 38098009
[TBL] [Abstract] [Full Text] [Related]
10. Exploration of the Mechanism of Kaempferol in the Treatment of cervical cancer-based on Metabolomics and Network Pharmacology.
Cao DM; Liu T
Curr Pharm Des; 2023; 29(36):2877-2890. PubMed ID: 38062663
[TBL] [Abstract] [Full Text] [Related]
11. Total Flavonoids in
He M; Yasin K; Yu S; Li J; Xia L
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003540
[TBL] [Abstract] [Full Text] [Related]
12. Exploring the utility of FTS as a bonafide binding partner for egfr: A potential drug target for cervical cancer.
Krishnamoorthy S; Muruganantham B; Yu JR; Park WY; Muthusami S
Comput Biol Med; 2023 Dec; 167():107592. PubMed ID: 37976824
[TBL] [Abstract] [Full Text] [Related]
13. A comparative analysis of phyto-components on egfr binding, viability, and migration in HPV positive ME180 and HPV negative C33A cervical cancer cells.
Sabanayagam R; Krishnamoorthy S; Anbuselvam M; Muruganantham B; Muthusami S
Med Oncol; 2023 Nov; 40(12):357. PubMed ID: 37964051
[TBL] [Abstract] [Full Text] [Related]
14. Increased Gene Expression of
Parida P; Lewis S; Sharan K; Kamal MV; Kumar NAN; Godkhindi VM; Varambally S; Rangnekar VM; Rao M; Damerla RR
Cells; 2023 Oct; 12(21):. PubMed ID: 37947608
[No Abstract] [Full Text] [Related]
15. Development and Assessment of 1,5-Diarylpyrazole/Oxime Hybrids Targeting egfr and JNK-2 as Antiproliferative Agents: A Comprehensive Study through Synthesis, Molecular Docking, and Evaluation.
Abdelrahman KS; Hassan HA; Abdel-Aziz SA; Marzouk AA; Shams R; Osawa K; Abdel-Aziz M; Konno H
Molecules; 2023 Sep; 28(18):. PubMed ID: 37764297
[TBL] [Abstract] [Full Text] [Related]
16. Ruthenium(II) polypyridyl complexes with visible light-enhanced anticancer activity and multimodal cell imaging.
Kang Y; Zhao Y; Wei Y; Zhang Y; Wang Z; Luo Q; Du J; Wang F
Dalton Trans; 2023 Sep; 52(35):12478-12489. PubMed ID: 37602756
[TBL] [Abstract] [Full Text] [Related]
17. EGCG attenuate EGF triggered matrix abundance and migration in HPV positive and HPV negative cervical cancer cells.
Sabanayagam R; Krishnamoorthy S; Gnanagurusamy J; Muruganatham B; Muthusami S
Med Oncol; 2023 Aug; 40(9):261. PubMed ID: 37544940
[TBL] [Abstract] [Full Text] [Related]
18. Cytotoxic activity of quinolinequinones in cancer: In vitro studies, molecular docking, and ADME/PK profiling.
Jannuzzi AT; Yilmaz Goler AM; Shilkar D; Mondal S; Basavanakatti VN; Yıldırım H; Yıldız M; Çelik Onar H; Bayrak N; Jayaprakash V; TuYuN AF
Chem Biol Drug Des; 2023 Nov; 102(5):1133-1154. PubMed ID: 37537000
[TBL] [Abstract] [Full Text] [Related]
19. Study on the mechanism of Shujin Tongluo granules in treating cervical spondylosis based on network pharmacology and molecular docking.
Wang Y; Tao X; Gao Y; Jin Z; Guo S; Li Z; Wang M; Zhao R; Zhou W; Wu J
Medicine (Baltimore); 2023 Jul; 102(29):e34030. PubMed ID: 37478234
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy and safety of egfr inhibitor gefitinib in recurrent or metastatic cervical cancer: a preliminary report.
Krishna A; Sathya M; Mukesh S; Athiyamaan MS; Banerjee S; Sunny J; Srinivas C; Lobo D; Makkapatti BS; Jawahar V
Med Oncol; 2023 Jun; 40(7):203. PubMed ID: 37310466
[TBL] [Abstract] [Full Text] [Related]
[Next]
